Hengrui Medicine: HRS-5041 tablets received drug clinical trial approval notice

2025-07-31 16:54:47

Hengrui Medicine announced that the company and its subsidiary, Chengdu Shengdi Pharmaceutical Co., Ltd., recently received approval from the National Medical Products Administration (NMPA) for the clinical trial of HRS-5041 tablets. Clinical trials will commence soon. HRS-5041 is a novel, highly potent, and selective AR-PROTAC (androgen receptor-protein degradation targeting chimera) small molecule developed by the company for the treatment of prostate cancer. To date, the company has invested approximately 69.19 million yuan in R&D related to the HRS-5041 tablets program.

Email Subscription

Newsletters and emails are now available! Delivered on time, every weekday, to keep you up to date with North American business news.

Weekly Highlights

                                    Novo Nordisk (NVO.N): The downward revision of its fiscal year sales forecast is related to declining sales of its weight loss drug Wegovy in the United States.
                            2025-07-29

                                    Toyota Motor Corp. is expected to decide as early as Wednesday evening whether to resume operations at its Japanese factories.
                            2025-07-30

                                    The world's first active safety AI battery cell goes into mass production
                            2025-07-27

                                    CATL's losses widened in the afternoon, with A shares falling more than 4% to below 280 yuan and H shares falling more than 7%.
                            2025-07-30

                                    BYD: Sales of new energy vehicles in July were 344,296 units. The cumulative sales of new energy vehicles from January to July were 2,490,250 units, a year-on-year increase of 27.35%.
                            2025-08-01